Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Array BioPharma (ARRY) PT Raised to $20 at Leerink Partners
February 7, 2018 7:40 AM ESTLeerink Partners raised its price target on Array BioPharma (NASDAQ: ARRY) to $20.00 (from $19.00) while maintaining a Outperform rating.
... MoreArray BioPharma (ARRY) PT Raised to $19 at Cowen
February 7, 2018 7:05 AM ESTCowen raised its price target on Array BioPharma (NASDAQ: ARRY) to $19.00 (from $17.00) while maintaining a Outperform rating.
Analyst Chris Shibutani commented, "F2Q18 results were highlighted by impressive pipeline updates including COLUMBUS data with greater than expected OS of 33.6 months for COMBO450 in BRAF-mutant... More
Array BioPharma (ARRY) PT Raised to $23 at Stifel
February 7, 2018 6:27 AM ESTStifel raised its price target on Array BioPharma (NASDAQ: ARRY) to $23.00 (from $20.00) while maintaining a Buy rating.
Analyst Stephen Willey commented, "The disclosure of median OS data from the P3 COLUMBUS trial (encorafenib/binimetinib vs. vemurafenib in BRAF-mutant melanoma) provides further confirmation of the pharmacological... More
Array Biopharma (ARRY) Tops Q2 EPS by 6c
February 6, 2018 8:08 AM ESTArray Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $42.2 million versus the consensus estimate of $26.67 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
... More